OVN — Oventus Medical Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -127.4% | ||
Return on Equity | -127.04% | ||
Operating Margin | -965.22% |
Financial Summary
Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 0.54 | 0.27 | 0.33 | 0.42 | 1.09 | 1.3 | 3 | 14.52% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Oventus Medical Limited is an Australia-based medical device company. The Company is commercializing a treatment platform for obstructive sleep apnea (OSA) and snoring. The Company’s O2Vent devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The Company’s product offerings include Oventus O2Vent Optima, O2Vent Optima, the ExVent and O2Vent Optima Mini. The Oventus O2Vent Optima product range provides relief to people who suffer snoring or mild to moderate OSA, and those who are unable to tolerate continuous positive airway pressure (CPAP) therapy. Its O2Vent Optima is an oral appliance, which features an integrated airway, using its own airway technology to treat the upper airway. It provides an uninterrupted airflow during sleep, as well as when a patient experiences nasal obstruction.
Directors
- John Cox CEO
- Daniel Parry CFO
- Robin Randolph SVP
- Christopher Hart EDR
- Stephen Denaro SEC
- Sharad Joshi NID
- Sue MacLeman NID
- Paul Molloy NID (55)
- Jake Nunn NID (45)
- Last Annual
- June 30th, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- September 23rd, 2015
- Public Since
- July 19th, 2016
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS
- Shares in Issue
- 241,726,535

- Address
- 1 Swann Road, Indooroopilly,, BRISBANE, 4068
- Web
- https://o2vent.com/
- Phone
- +61 300533159
- Auditors
- PKF BRISBANE
Upcoming Events for OVN
Similar to OVN
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Orthopaedics
Australian Stock Exchange - SEATS
Analytica
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:16 UTC, shares in Oventus Medical are trading at AU$0.02. This share price information is delayed by 15 minutes.
Shares in Oventus Medical last closed at AU$0.02 and the price had moved by -82.98% over the past 365 days. In terms of relative price strength the Oventus Medical share price has underperformed the ASX All Ordinaries Index by -84.16% over the past year.
The overall consensus recommendation for Oventus Medical is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOventus Medical does not currently pay a dividend.
Oventus Medical does not currently pay a dividend.
Oventus Medical does not currently pay a dividend.
To buy shares in Oventus Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.02, shares in Oventus Medical had a market capitalisation of .
Here are the trading details for Oventus Medical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: OVN
Based on an overall assessment of its quality, value and momentum Oventus Medical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oventus Medical. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -78.35%.
As of the last closing price of AU$0.02, shares in Oventus Medical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oventus Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oventus Medical's management team is headed by:
- John Cox - CEO
- Daniel Parry - CFO
- Robin Randolph - SVP
- Christopher Hart - EDR
- Stephen Denaro - SEC
- Sharad Joshi - NID
- Sue MacLeman - NID
- Paul Molloy - NID
- Jake Nunn - NID